Concepedia
Statistics
Publications
4
Citations
217
H-Index
Active since
2014
Affiliations
Gilead Sciences (United States)(Current)
Georgetown University
Oregon Health & Science University
Charleston Hematology Oncology Associates
University of Rochester Medical Center
Esteban Abella-Dominicis is an author at Gilead Sciences (United States) specializing in medicine, pharmacology, and pharmacotherapy.
Publications per year
2014–2019
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Blood · 2016 · 142 citations
Medicine, Pharmacology, Pharmacotherapy +7
Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
Andrea Necchi, Daniel Castellano, Begoña Mellado et al. · Journal of Clinical Oncology · 2019 · 43 citations
Medicine, Oncology, Pharmacology +17
Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Journal of Clinical Oncology · 2014 · 17 citations
Medicine, Pharmacology, Pharmacotherapy +15
Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia
Alison R. Walker, Bhavana Bhatnagar, A. Mario Marcondes et al. · Blood · 2016 · 15 citations
Medicine, Oncology, Pharmacokinetics +9
1–4 of 4